Floatz logo

IBRITUMOMAB TIUXETAN

AIDS-related Lymphoma

AIDS Malignancy Consortiummonoclonal_antibodyPhase 2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

20 Active assets in the AIDS-related Lymphoma cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 2BBB
ETOPOSIDE
National Cancer Institute (NCI)
Phase 2BBB
Inno-206
National Cancer Institute (NCI)
Phase 2BBB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
National Cancer Institute (NCI)
Phase 2BB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 2BB

View all 47 →

Same molecule, other indications

IBRITUMOMAB TIUXETAN is also rated in:

non-Hodgkin lymphomaDormant
BB
Indicative ·
68 / 100
View asset →
Lymphoma, Low-GradeDormant
BB
Indicative ·
66 / 100
View asset →
non-Hodgkin lymphomaDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →